window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 22, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Sanofi Ventures

  • Biotech & Pharma Business,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Bionyra launches with $165M Series A to advance immunology biologics pipeline

    bionyra-pharma-series-a-immunology Bionyra Pharma has launched with a $165 million Series [...]

    June 22, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Opinion & Events,Pharmaceuticals and therapeutics

    QuantHealth secures strategic investment from Sanofi Ventures to accelerate AI-driven clinical trials

    QuantHealth, a pioneer in AI-driven clinical trial simulation, has received [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Manufacturing & Supply Chain

    SpliceBio secures $135 Million series B to advance dual-AAV therapy for Stargardt Disease

    Funding will support clinical development of SB-007 and expand pipeline [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Adneuris licenses Phase 3 pain therapy cebranopadol to Conba for Greater China
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics
  • Latent Labs opens lab-validated AI drug design platform to researchers worldwide
    Categories: Digital & Data, Drug Discovery & Development, Research & Development
  • PET imaging reveals widespread synaptic loss in schizophrenia
    Categories: Clinical & Regulatory, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top